Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

Lonza Group Ag (OTCMKTS:LZAGY) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 8,172 shares, a decrease of 62.7% from the January 29th total of 21,908 shares. Based on an average daily volume of 428,761 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 428,761 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Several research firms have issued reports on LZAGY. Royal Bank Of Canada upgraded Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Zacks Research cut shares of Lonza Group from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Lonza Group Stock Up 0.7%

Shares of OTCMKTS:LZAGY traded up $0.51 during midday trading on Friday, reaching $69.33. The company’s stock had a trading volume of 69,462 shares, compared to its average volume of 113,943. The business’s fifty day simple moving average is $68.45 and its 200-day simple moving average is $68.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24. Lonza Group has a fifty-two week low of $55.57 and a fifty-two week high of $73.85.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.